At TKG Therapeutics, Inc., we are dedicated to transforming the landscape of cancer therapy by developing innovative, targeted treatments with the potential to save millions of lives. Our groundbreaking Oncolytic Hairpin DNA Pair technology is poised to revolutionize cancer treatment by offering a highly selective and immune-activating therapy that targets cancer cells with high miRNA expression.

Our Oncolytic Hairpin DNA Pair technology has demonstrated promising results in both in vitro and in vivo experiments, selectively killing cancer cells while leaving healthy cells unharmed. By harnessing the power of microRNA-triggered DNA self-assembly, our technology induces innate immune activation, specifically targeting the cGAS-STING pathway - a universal innate immune mechanism present in most patients and cancer cells.

​

Key advantages;

 

High Selectivity: Targets cancer cells with high miRNA expression, a common feature in various types of cancers, while sparing healthy cells to minimize side effects.

Immune Activation: Stimulates the body's natural immune response against cancer cells by selectively activating the cGAS-STING pathway.

Versatile Treatment: With over 1,000 different miRNAs related to various cancers, our technology holds the potential to treat a wide range of tumor types.

Combination Therapy Potential: Our hairpin DNA system can be combined with existing immune checkpoint inhibitors for a more effective and comprehensive cancer immunotherapy approach.